The Jordi Gol Institute and Bioibérica Farma sign a partnership agreement to encourage research in the field of joint healthcare
The Jordi Gol Institute for Research in Primary Care (IDIAP) and Bioiberica Farma have signed a five-year research partnership agreement. Its objective is to boost biomedical research in the field of primary care, and, to be more precise, in the field of osteoarthritis. This partnership project aims to achieve new research milestones in the field of joint care.
In fact, there are more than one million osteoarthritis patients in Catalonia. Osteoarthritis it is a chronic and inflammatory disease that affects the joints and causes pain and loss of mobility. 30% of all temporary and permanent sick leaves and 35% of visits to primary care physicians are caused by osteoarthritis.
This agreement aims to improve the medical attention given to large numbers of primary care patients, most of them affected by joint diseases.
According to the Jordi Gol Institute director, Dr. Concepció Violan, , the signature of this agreement will allow primary care services to improve their level of scientific knowledge on joint diseases, which are highly prevalent, and at the same time reinforce the task carried out by the IDIAP, that of encouraging research in primary care.
Clinical pharmacologist and medical and scientific director of Bioibérica Farma, Dr. Josep Vergés, said that the latest research projects intend to demonstrate, in the daily clinical practice, how therapeutic treatments can reduce osteoarthritis-related expenditure and improve the life quality of osteoarthritis patients. At Bioibérica we are glad to undertake scientific cooperation with the Jordi Gol Institute, as we have done before with other first-line national and international institutes such as FNIH, NICE, OMERACT or CNRS, among others.
What is the IDIAP?
The Jordi Gol i Gurina foundation was created in 1996 under the auspices the Institut Català de la Salut (Catalan Healthcare Service) in order to promote and manage innovation, education, teaching and research (clinical and epidemiological) in the field of primary care services.
In 2006 the The Jordi Gol Foundation became the Institute of Research in Primary Care (Institut dInvestigación en Atenció Primària Jordi Gol, IDIAP Jordi Gol). In 2010 it became one of the University Institutes in Primary Care Research of the UAB (Universitat Autónoma de Barcelona, Autonomous University of Barcelona). In August 2011 it was granted the ISO 9001:2008 quality certification because of the support and advice given to a number of research projects.
What is Bioibérica Farma?
Bioibérica Farma is a Catalan chemical-pharmaceutical company founded in 1975 specializing in the treatment of osteoarthritis. It is currently developing a number of research lines about that disease. These lines of research aim at identifying the physiopathological mechanisms and genetic factors associated to osteoarthritis, as well as to confirm the efficacy and security of chondroprotector drugs.
At the social level, the aims of Bioibérica are to improve the life quality of osteoarthritis patients, as well as to reduce overall cost of that disease. This is the reason why we are developing a number of lines of research that include pharmacogenetics, pharmacoproteomics, diagnosis and prognostic chips, bio markers, and cell therapy.
www.comunicacionbioibericafarma.es
For further information please contact:
IDIAP Press- Ester Duran premsa@idiapjgol.org +34 659 44 27 95
Bioibérica Farma communication- Alba Soler asoler@bioiberica.com
